Notch signalling pathway in development of cholangiocarcinoma.

Autor:	Rauff B; Institute of Molecular Biology and Biotechnology, University of Lahore, Lahore 54000, Pakistan. bisma.rauff@imbb.uol.edu.pk., Malik A; Institute of Molecular Biology and Biotechnology, University of Lahore, Lahore 54000, Pakistan., Bhatti YA; Institute of Molecular Biology and Biotechnology, University of Lahore, Lahore 54000, Pakistan., Chudhary SA; Institute of Biomedical and Allied Health Sciences, University of Health Sciences, Lahore 54000, Pakistan., Qadri I; Department of Biology, Faculty of Science, King Abdulaziz University Jeddah Kingdom of Saudi Arabia., Rafiq S; Department of Gastrointestinal medicine, Croydon University Hospital, Croydon CR7 7YE, United Kingdom.
Jazyk:	angličtina
Zdroj:	World journal of gastrointestinal oncology [World J Gastrointest Oncol] 2020 Sep 15; Vol. 12 (9), pp. 957-974.
DOI:	10.4251/wjgo.v12.i9.957
Abstrakt:	Cholangiocarcinoma (CCA) comprises of extra-hepatic cholangiocarcinoma and intrahepatic cholangiocarcinoma cancers as a result of inflammation of epithelium cell lining of the bile duct. The incidence rate is increasing dramatically worldwide with highest rates in Eastern and South Asian regions. Major risk factors involve chronic damage and inflammation of bile duct epithelium from primary sclerosing cholangitis, chronic hepatitis virus infection, gallstones and liver fluke infection. Various genetic variants have also been identified and as CCA develops on the background of biliary inflammation, diverse range of molecular mechanisms are involved in its progression. Among these, the Notch signalling pathway acts as a major driver of cholangiocarcinogenesis and its components (receptors, ligands and downstream signalling molecules) represent a promising therapeutic targets. Gamma-Secretase Inhibitors have been recognized in inhibiting the Notch pathway efficiently. A comprehensive knowledge of the molecular pathways activated by the Notch signalling cascade as well as its functional crosstalk with other signalling pathways provide better approach in developing innovative therapies against CCA. Competing Interests: Conflict-of-interest statement: The authors declare no potential financial interests. (©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu